Elanco Animal Health ELAN
Elanco has destroyed billions under CEO Simmons and an insular classified board; replacing four directors at the 2024 AGM installs accountability and unlocks the animal-health turnaround.
Thesis
Ancora, a ~3% holder, argues that Elanco — a top-four global animal health franchise in a secularly growing market — has destroyed billions of dollars in shareholder value under CEO Jeffrey Simmons and an entrenched, classified Board. Since the 2019 Bayer Animal Health acquisition, ELAN has fallen ~50%, leaving a $5.5B debt load and missing every margin and growth target set at the IPO, the Bayer deal and the 2020 Investor Day (gross margin 56.1% vs 60% commitment; EBITDA 22.2% vs 31%). Management repeatedly invokes an 'inflection point' to deflect accountability while ISS has recommended against nine of thirteen directors at recent meetings. Ancora is running a proxy contest to replace four 2024-class directors — including Simmons — with nominees Kathy Turner, Craig Wallace, James Chadwick and Andrew Clarke, who bring animal-health, supply-chain and capital-allocation expertise to drive a multi-year turnaround.
SCQA
Elanco Animal Health is a top-four global animal-health company in a secularly growing industry, spun out of Eli Lilly in 2018 and bulked up by the 2019 Bayer Animal Health acquisition.
Under CEO Jeffrey Simmons and a classified, interconnected board, ELAN has missed every IPO/Bayer/2020 Investor Day target, eroded margins, levered to $5.5B in debt and posted -45.5% TSR while peers gained 61.9%.
Vote four Ancora nominees (Turner, Wallace, Chadwick, Clarke) onto the Board at the 2024 Annual Meeting to replace Doyle, Garcia, Scots-Knight and Simmons, then drive CEO succession and a public margin-improvement plan.
Closing the 54% NTM EBITDA-multiple compression and the gap to ZTS/correlated peers (~+107 percentage points of TSR) reverses years of value destruction and re-rates Elanco toward its animal-health peer set.
The three reasons
- 1
ELAN down 45.5% since 2019 vs. peers up 61.9%; -62% TSR under CEO Simmons
- 2
Bayer Animal Health deal destroyed value, left $5.5B debt and missed every IPO/Investor Day target
- 3
Entrenched classified board with industry-worst governance has shielded management from accountability
Primary demands
- Replace four 2024 class directors (Doyle, Garcia, Scots-Knight, Simmons) with Ancora's four nominees
- Initiate orderly CEO succession process to replace Jeffrey Simmons
- Publicly commit to specific margin improvement targets and timeline
- Establish a culture of accountability and execution at the Board level
- Add direct animal-health, supply-chain and capital-allocation expertise to the Board
KPIs cited
Pattern membership
Where this document fits across the library's 12 rhetorical / structural patterns.
Precedents cited
- Mueller Industries — 2022 board refresh and Capital Allocation Committee
- Berry Global — 2022 board refresh, HH&S strategic review, new CEO
- RB Global (Ritchie Bros / IAA) — 2023 independent designee and IAA-Ritchie Bros transaction
- Starboard Value's 2021 nomination of three directors to Elanco's board
Notable slides (6)
Notes
Classic governance-driven proxy fight deck. Strongest rhetorical move is the 'inflection point' contradiction (slide 8 + timeline on slide 20) showing Simmons recycling the same line from 2020-2023 while TSR collapsed. Slide 10 personalises blame with director-by-director TSR scorecards. Margin-commitment slide 22 is the cleanest execution-failure visual. Stake of ~3% disclosed in situation overview (slide 6). Ancora cites its own prior campaigns (Mueller, Berry, RB Global) as a track-record proof — a playbook signal worth flagging.